204 related articles for article (PubMed ID: 22374758)
21. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
22. Different transcriptional control of metabolism and extracellular matrix in visceral and subcutaneous fat of obese and rimonabant treated mice.
Poussin C; Hall D; Minehira K; Galzin AM; Tarussio D; Thorens B
PLoS One; 2008; 3(10):e3385. PubMed ID: 19030233
[TBL] [Abstract][Full Text] [Related]
23. Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis.
Preitner F; Mody N; Graham TE; Peroni OD; Kahn BB
Am J Physiol Endocrinol Metab; 2009 Dec; 297(6):E1420-9. PubMed ID: 19826103
[TBL] [Abstract][Full Text] [Related]
24. Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
Chen W; Chen Z; Xue N; Zheng Z; Li S; Wang L
Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug; 386(8):721-32. PubMed ID: 23620336
[TBL] [Abstract][Full Text] [Related]
25. Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis.
O'Hare JD; Zielinski E; Cheng B; Scherer T; Buettner C
Diabetes; 2011 Apr; 60(4):1055-62. PubMed ID: 21447652
[TBL] [Abstract][Full Text] [Related]
26. Diet-induced obesity prevents interstitial dispersion of insulin in skeletal muscle.
Kolka CM; Harrison LN; Lottati M; Chiu JD; Kirkman EL; Bergman RN
Diabetes; 2010 Mar; 59(3):619-26. PubMed ID: 19959760
[TBL] [Abstract][Full Text] [Related]
27. Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice.
Chen B; Hu N
Braz J Med Biol Res; 2017 May; 50(6):e6141. PubMed ID: 28492810
[TBL] [Abstract][Full Text] [Related]
28. Beta-cell "rest" accompanies reduced first-pass hepatic insulin extraction in the insulin-resistant, fat-fed canine model.
Kim SP; Ellmerer M; Kirkman EL; Bergman RN
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1581-9. PubMed ID: 17284579
[TBL] [Abstract][Full Text] [Related]
29. Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.
Bajzer M; Olivieri M; Haas MK; Pfluger PT; Magrisso IJ; Foster MT; Tschöp MH; Krawczewski-Carhuatanta KA; Cota D; Obici S
Diabetologia; 2011 Dec; 54(12):3121-31. PubMed ID: 21987346
[TBL] [Abstract][Full Text] [Related]
30. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice.
Yu XX; Watts LM; Manchem VP; Chakravarty K; Monia BP; McCaleb ML; Bhanot S
PLoS One; 2013; 8(7):e66923. PubMed ID: 23922646
[TBL] [Abstract][Full Text] [Related]
31. Reduced insulin suppression of glucose appearance is related to susceptibility to dietary obesity in rats.
Pagliassotti MJ; Horton TJ; Gayles EC; Koppenhafer TA; Rosenzweig TD; Hill JO
Am J Physiol; 1997 Apr; 272(4 Pt 2):R1264-70. PubMed ID: 9140029
[TBL] [Abstract][Full Text] [Related]
32. Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant.
Martín-García E; Burokas A; Martín M; Berrendero F; Rubí B; Kiesselbach C; Heyne A; Gispert JD; Millán O; Maldonado R
J Neurochem; 2010 Mar; 112(5):1338-13351. PubMed ID: 20028452
[TBL] [Abstract][Full Text] [Related]
33. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
Thornton-Jones ZD; Kennett GA; Benwell KR; Revell DF; Misra A; Sellwood DM; Vickers SP; Clifton PG
Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374
[TBL] [Abstract][Full Text] [Related]
34. Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice.
Mohapatra J; Sharma M; Singh S; Pandya G; Chatterjee A; Balaraman R; Patel PR; Jain MR
J Pharm Pharmacol; 2009 Nov; 61(11):1493-8. PubMed ID: 19903374
[TBL] [Abstract][Full Text] [Related]
35. Activation of NPRs and UCP1-independent pathway following CB1R antagonist treatment is associated with adipose tissue beiging in fat-fed male dogs.
Iyer MS; Paszkiewicz RL; Bergman RN; Richey JM; Woolcott OO; Asare-Bediako I; Wu Q; Kim SP; Stefanovski D; Kolka CM; Clegg DJ; Kabir M
Am J Physiol Endocrinol Metab; 2019 Sep; 317(3):E535-E547. PubMed ID: 31237449
[TBL] [Abstract][Full Text] [Related]
36. Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages.
Miranville A; Herling AW; Biemer-Daub G; Voss MD
Obesity (Silver Spring); 2010 Dec; 18(12):2247-54. PubMed ID: 20379144
[TBL] [Abstract][Full Text] [Related]
37. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice.
Liu J; Zhou L; Xiong K; Godlewski G; Mukhopadhyay B; Tam J; Yin S; Gao P; Shan X; Pickel J; Bataller R; O'Hare J; Scherer T; Buettner C; Kunos G
Gastroenterology; 2012 May; 142(5):1218-1228.e1. PubMed ID: 22307032
[TBL] [Abstract][Full Text] [Related]
38. The effect of cannabinoid receptor 1 blockade on adipokine and proinflammatory cytokine concentration in adipose and hepatic tissue in mice with nonalcoholic fatty liver disease.
Jorgačević B; Vučević D; Vesković M; Mladenović D; Vukićević D; Vukićević RJ; Todorović V; Radosavljević T
Can J Physiol Pharmacol; 2019 Feb; 97(2):120-129. PubMed ID: 30673308
[TBL] [Abstract][Full Text] [Related]
39. Addition of a low dose of rimonabant to orlistat therapy decreases weight gain and reduces adiposity in dietary obese rats.
Zaitone SA; Essawy S
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):551-9. PubMed ID: 22524969
[TBL] [Abstract][Full Text] [Related]
40. A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys.
Wagner JD; Zhang L; Kavanagh K; Ward GM; Chin JE; Hadcock JR; Auerbach BJ; Harwood HJ
J Pharmacol Exp Ther; 2010 Oct; 335(1):103-13. PubMed ID: 20605903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
